MB
MPM BioImpact Portfolio holdings
AUM
$577M
This Quarter Return
-30.53%
1 Year Return
+8.33%
3 Year Return
+241.63%
5 Year Return
+127.38%
10 Year Return
–
AUM
$164M
AUM Growth
+$164M
(-42%)
Cap. Flow
-$33M
Cap. Flow
% of AUM
-20.15%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
13
New
1
Increased
–
Reduced
–
Closed
3
Top Buys
| 1 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
$13.8M |
Top Sells
| 1 |
ARQL
Arqule Inc
ARQL
|
$21.8M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$13.4M |
| 3 |
argenx
ARGX
|
$11.5M |
Sector Composition
| 1 | Healthcare | 93.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HARP
1
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $45.1M | 27.58% | 3,898,422 | – | – |
|
|
EPZM
2
DELISTED
Epizyme, Inc
EPZM
| $36.2M | 22.09% | 2,331,534 | – | – |
|
|
TCRR
3
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $26.1M | 15.94% | 3,370,982 | – | – |
|
|
GTHX
4
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $15.7M | 9.58% | 1,423,794 | – | – |
|
|
TPTX
5
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $13.8M | 8.42% | +308,686 | New | +$13.8M |
|
6
Y-mAbs Therapeutics
YMAB
$388M
| $8.8M | 5.38% | 337,291 | – | – |
|
7
CytomX Therapeutics
CTMX
$336M
| $6.56M | 4.01% | 855,437 | – | – |
|
|
VIRX
8
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $1.17M | 0.71% | 2,809,912 | – | – |
|
|
AUTL
9
Autolus Therapeutics
AUTL
$399M
| $238K | 0.15% | 39,740 | – | – |
|
|
10
argenx
ARGX
$43.6B
| – | – | -71,700 | Closed | -$11.5M |
|
|
DCPH
11
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| – | – | -215,570 | Closed | -$13.4M |
|
|
ARQL
12
DELISTED
Arqule Inc
ARQL
| – | – | -1,094,210 | Closed | -$21.8M |
|